|
o
|
Preliminary Proxy
Statement
|
|
|
o
|
Confidential, for Use of the
Commission Only (as permitted by
Rule 14a-6(e)(2))
|
|
|
o
|
Definitive Proxy
Statement
|
|
|
þ
|
Definitive Additional
Materials
|
|
|
o
|
Soliciting Material Pursuant to
§240.14a-12
|
|
þ
|
No fee
required.
|
|||
|
o
|
Fee computed on table
below per Exchange
Act Rules 14a-6(i)(4) and 0-11.
|
|||
|
1)
|
Title of each class of securities
to which transaction applies:
|
|||
|
2)
|
Aggregate number of securities to
which transaction applies:
|
|||
|
3)
|
Per unit price or other underlying
value of transaction
computed pursuant to Exchange Act Rule 0-11 (set forth the amount on
which the filing fee is calculated and state how it was
determined):
|
|||
|
4)
|
Proposed maximum aggregate value
of transaction:
|
|||
|
5)
|
Total fee
paid:
|
|||
|
o
|
Fee paid previously with
preliminary materials.
|
|||
|
o
|
Check box if any part of the fee
is offset as provided by Exchange Act Rule 0-11(a)(2) and identify
the filing for which the offsetting fee was paid previously. Identify the
previous filing by
registration statement number, or the Form or Schedule and the date of its
filing.
|
|||
|
1)
|
Amount Previously
Paid:
|
|||
|
2)
|
Form, Schedule or Registration
Statement No.:
|
|||
|
3)
|
Filing
Party:
|
|||
|
4)
|
Date
Filed:
|
|||
|
|
·
|
The
significant growth in revenues, profits, earnings per share, net income
margins and cumulative returns for each of the past five years produced
under the company’s continuing Board nominees and the current management
team, which has unanimously endorsed Quality Systems’
slate;
|
|
|
·
|
A
clearly articulated strategy that capitalizes on the potential of the
rapidly growing healthcare industry;
and
|
|
|
·
|
Endorsements
from RiskMetrics, Glass Lewis and Proxy Governance, the country’s three
leading proxy advisor services, each of which recommended shareholders
fully support the Quality Systems
nominees.
|